Michele Gerber, MD, MPH
Dr. Gerber is a rheumatologist with over 15 years of research and clinical experience at the University of Michigan and over 12 years of experience as a clinical immunologist in the pharmaceutical industry. She has been a leader in global clinical phase 1-4 trials, studying many ground-breaking therapeutics.
Prior to Myeloid, Dr. Gerber served as the Global Clinical Lead at Takeda for a stem cell therapy for Crohn’s perianal fistula, which was approved in Europe and is being studied in the US and Japan. She was also the Clinical Lead at Takeda for TIMP-GLIA, a nanoparticle for celiac disease and the first therapeutic shown to induce tolerance in any autoimmune disease. Additionally, she has contributed to multiple INDs and NDAs. Dr. Gerber obtained her MD and MPH at the University of Michigan.